Cite
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
MLA
Clamp, Andrew R., et al. “Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Treatment (ICON8): Primary Progression Free Survival Analysis Results from a GCIG Phase 3 Randomised Controlled Trial.” Lancet (London, England), vol. 394, no. 10214, Dec. 2019, pp. 2084–95. EBSCOhost, https://doi.org/10.1016/S0140-6736(19)32259-7.
APA
Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J.-W., O’Donnell, D. M., Hook, J., Coyle, C., Blagden, S., Brenton, J. D., Naik, R., Perren, T., Sundar, S., Cook, A. D., Gopalakrishnan, G. S., Gabra, H., Lord, R., Dark, G., Earl, H. M., … Ledermann, J. A. (2019). Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet (London, England), 394(10214), 2084–2095. https://doi.org/10.1016/S0140-6736(19)32259-7
Chicago
Clamp, Andrew R, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Weon Kim, Dearbhaile M O’Donnell, Jane Hook, et al. 2019. “Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Treatment (ICON8): Primary Progression Free Survival Analysis Results from a GCIG Phase 3 Randomised Controlled Trial.” Lancet (London, England) 394 (10214): 2084–95. doi:10.1016/S0140-6736(19)32259-7.